GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Other Stockholders Equity

UPB (Upstream Bio) Other Stockholders Equity : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Upstream Bio Other Stockholders Equity?

Upstream Bio's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.

Upstream Bio Other Stockholders Equity Historical Data

The historical data trend for Upstream Bio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Upstream Bio Other Stockholders Equity Chart

Upstream Bio Annual Data
Trend Dec22 Dec23
Other Stockholders Equity
- -

Upstream Bio Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial - - - - -

Upstream Bio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Upstream Bio Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Upstream Bio's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Upstream Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Upstream Bio Inc (NAS:UPB) » Definitions » Other Stockholders Equity
Comparable Companies
Traded in Other Exchanges
N/A
Address
890 Winter Street, Suite 200, Waltham, MA, USA, 02451
Website
https://www.upstreambio.com
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.